Diazepam is a drug used to treat mild to moderate anxiety and tension and to relax muscles. It is a type of benzodiazepine. Also called Valium.
Researchers at Emory University School of Medicine have discovered that dozens of adults with an elevated need for sleep have a substance in their cerebrospinal fluid that acts like a sleeping pill.
For a long time there was a controversy about how anesthetics work. The large number of molecules that have anesthetic properties (from benzodiazepines to nitrous oxide) and their very different structures...
Drugs prescribed to treat anxiety, depression and insomnia may increase patients’ risk of being involved in motor vehicle accidents, according to a recent study, published in the British Journal of Clinical Pharmacology. Based on the findings, the researchers suggested doctors should consider advising patients not to drive while taking these drugs.
A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).
One in five prescriptions in primary care for the elderly is inappropriate, say the authors of a systematic review.
SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.
SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that the first patient was dosed in a phase 2 clinical trial in the US for patients suffering with chronic constipation using their new chemical entity YKP10811.
Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.
Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.
The mould fungus Penicillium crustosum occurs relatively frequently in food and animal fodder stored in temperate conditions. This mould produces powerful neurotoxins, for example penitrem A, which causes symptoms that are difficult to distinguish from those of other neurological diseases.
We all know that people and animals can be harmed by excessive heat; so can medications, states Dr. Amy Peak, director of Drug Information Services for Butler University.
Most synthetic chemical products used in consumer goods end up unchanged in the environment. Given the risks this could pose for the environment and human health, researchers from the Autonomous University of Barcelona (UAB) have developed a new tool to effectively predict what will happen to current and future pharmaceutical products.
Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).
ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.
In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.
Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection.
ChromaDex Corp. and the University of Mississippi today announced the university has granted the natural products company the exclusive worldwide patent rights to a potential new therapeutic use for pterostilbene (tero-STILL-bean) as an anxiolytic or anti-anxiety agent. ChromaDex' pTeroPure® is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits.
Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.
Technology has been developed within Top Institute Pharma that helps medicines be absorbed quicker into the blood and thus be more effective. Researcher Hans de Waard, who is associated with the University of Groningen, will obtain his doctorate on this subject on March 11. De Waard: "Many current medicines are not easily dissolved in the digestive tract, which means that they barely reach the bloodstream.
Status epilepticus, prolonged seizures, can lead to significant neurological deficits and, rarely, even death. The anticonvulsant diazepam, a first line therapy for the condition, is neuroprotective when administered in high doses within two hours from seizure onset. Researchers at the 64th AES Annual Meeting now report that the combination of low-dose diazepam and NS-398, a COX-2 inhibitor, has twice the neuroprotective effect of NS-398 alone.